Abstract
Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have